Advertisement

Inflammation

pp 1–12 | Cite as

Mycobacterium tuberculosis–Secreted Protein, ESAT-6, Inhibits Lipopolysaccharide-Induced MMP-9 Expression and Inflammation Through NF-κB and MAPK Signaling in RAW 264.7 Macrophage Cells

  • Sun-Hyung Ha
  • Hyunju Choi
  • Jun-Young Park
  • Fukushi Abekura
  • Young-Choon Lee
  • Jeong-Ran KimEmail author
  • Cheorl-Ho KimEmail author
Original Article

Abstract

-20pt?>Mycobacterium tuberculosis (Mtb) is a pathogenic bacterium that causes contagious tuberculosis (TB). Recently, Mtb-secreted proteins have been considered virulence factors and candidates for drugs and vaccines. Among these proteins, 6-kDa early secreted antigenic target (ESAT-6) is known to be able to induce component of matrix metalloproteinase-9 (MMP-9) in epithelial cells, leading to recruitment of macrophages. However, detailed function of ESAT-6 during macrophage recruitment to inflammatory sites remains unknown. Thus, the objective of the present study was to elucidate such function of EAST-6 and mechanism(s) involved. In the present study, we have found that recombinant ESAT-6 purified in the form of ESAT-6 double-connected structure (2E6D) could inhibit lipopolysaccharide (LPS)-induced potential of cell migration and inflammation in murine macrophage cells. Interestingly, 2E6D suppressed LPS-induced MMP-9 expression at both protein and mRNA levels as well as its enzyme activity. Levels of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) enzymes as known upregulators of MMP-9 were significantly decreased when 2E6D has been treated. In addition, nitric oxide (NO) as a second messenger was also significantly decreased by treatment with the purified 2E6D. Furthermore, 2E6D inhibited LPS-induced phosphorylation of IκB and translocation of NF-κB. Moreover, 2E6D suppressed phosphorylation of MAPK signaling proteins. Taken together, these results suggest that ESAT-6 can suppress LPS-induced MMP-9 and inflammation by downregulating COX-2, iNOS, and NO through NF-κB and MAPK signaling.

Key Words

Mycobacterium tuberculosis ESAT-6 inflammation RAW 264.7 macrophage cells 

Notes

Acknowledgments

This study has collaboratively been carried out by a member of SKKU glycobiology laboratory due to its non-financial support.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

References

  1. 1.
    Bañuls, A.L., A. Sanou, N.T. Anh, and S. Godreuil. 2015. Mycobacterium tuberculosis: ecology and evolution of a human bacterium. Journal of Medical Microbiology 64: 1261–1269.CrossRefGoogle Scholar
  2. 2.
    Roy, A., M. Eisenhut, R.J. Harris, L.C. Rodrigues, S. Sridhar, I. Abubakar, et al. 2014. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 349: g4643.CrossRefGoogle Scholar
  3. 3.
    Velayati, A.A., M.R. Masjedi, P. Farnia, P. Tabarsi, J. Ghanavi, S.E. Hoffner, et al. 2009. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest. 136: 420–425.CrossRefGoogle Scholar
  4. 4.
    Migliori, G.B., R. Centis, L. D’Ambrosio, A. Spanevello, E. Borroni, and G. Sotgiu. 2012. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clinical Infectious Diseases 54: 1379–1380.CrossRefGoogle Scholar
  5. 5.
    Kashino, S.S., N. Pollock, D.R. Napolitano, V. Rodrigues Jr., and A. Campos-Neto. 2008. Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clinical and Experimental Immunology 153: 56–62.CrossRefGoogle Scholar
  6. 6.
    Napolitano, D.R., N. Pollock, S.S. Kashino, V. Rodrigues Jr., and A. Campos-Neto. 2008. Identification of Mycobacterium tuberculosis ornithine carboamyltransferase in urine as a possible molecular marker of active pulmonary tuberculosis. Clinical and Vaccine Immunology 15: 638–643.CrossRefGoogle Scholar
  7. 7.
    Harboe, M., T. Oettinger, H.G. Wiker, I. Rosenkrands, and P. Andersen. 1996. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infection and Immunity 64: 16–22.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Colangeli, R., J.S. Spencer, P. Bifani, A. Williams, K. Lyashchenko, M.A. Keen, P.J. Hill, J. Belisle, and M.L. Gennaro. 2000. MTSA-10, the product of the Rv3874 gene of Mycobacterium tuberculosis, elicits tuberculosis-specific, delayed-type hypersensitivity in guinea pigs. Infection and Immunity 68: 990–993.CrossRefGoogle Scholar
  9. 9.
    Trajkovic, V., G. Singh, B. Singh, S. Singh, and P. Sharma. 2002. Effect of Mycobacterium tuberculosis-specific 10-kilodalton antigen on macrophage release of tumor necrosis factor alpha and nitric oxide. Infection and Immunity 70: 6558–6566.CrossRefGoogle Scholar
  10. 10.
    Pym, A.S., P. Brodin, R. Brosch, M. Huerre, and S.T. Cole. 2002. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Molecular Microbiology 46: 709–717.CrossRefGoogle Scholar
  11. 11.
    Moliva, J.I., J. Turner, and J.B. Torrelles. 2017. Immune responses to bacillus Calmette-Guérin vaccination: why do they fail to protect against Mycobacterium tuberculosis? Frontiers in Immunology 8: 407.CrossRefGoogle Scholar
  12. 12.
    Lewis, K.N., R. Liao, K.M. Guinn, M.J. Hickey, S. Smith, D.R. Sherman, et al. 2003. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guérin attenuation. The Journal of Infectious Diseases 187: 117–123.CrossRefGoogle Scholar
  13. 13.
    Talbot, E.A., D.L. Williams, and R. Frothingham. 1997. PCR identification of Mycobacterium bovis BCG. Journal of Clinical Microbiology 35: 566–569.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Daugelat, S., J. Kowall, J. Mattow, D. Bumann, R. Winter, R. Hurwitz, and S.H.E. Kaufmann. 2003. The RD1 proteins of Mycobacterium tuberculosis: expression in Mycobacterium smegmatis and biochemical characterization. Microbes and Infection 5: 1082–1095.CrossRefGoogle Scholar
  15. 15.
    Dillon, D.C., M.R. Alderson, C.H. Day, T. Bement, A. Campos-Neto, Y.A. Skeiky, et al. 2000. Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. Journal of Clinical Microbiology 38: 3285–3290.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Sørensen, A.L., S. Nagai, G. Houen, P. Andersen, and A.B. Andersen. 1995. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infection and Immunity 63: 1710–1717.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Arend, S.M., A. Geluk, K.E. van Meijgaarden, J.T. van Dissel, M. Theisen, P. Andersen, and T.H.M. Ottenhoff. 2000. Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infection and Immunity 68: 3314–3321.CrossRefGoogle Scholar
  18. 18.
    Malik, Z.A., S.S. Iyer, and D.J. Kusner. 2001. Mycobacterium tuberculosis phagosomes exhibit altered calmodulin-dependent signal transduction: contribution to inhibition of phagosome-lysosome fusion and intracellular survival in human macrophages. Journal of Immunology 166: 3392–3401.CrossRefGoogle Scholar
  19. 19.
    Ting, L.M., A.C. Kim, A. Cattamanchi, and J.D. Ernst. 1999. Mycobacterium tuberculosis inhibits IFN-gamma transcriptional responses without inhibiting activation of STAT1. Journal of Immunology 163: 3898–3906.Google Scholar
  20. 20.
    Noss, E.H., C.V. Harding, and W.H. Boom. 2000. Mycobacterium tuberculosis inhibits MHC class II antigen processing in murine bone marrow macrophages. Cellular Immunology 201: 63–74.CrossRefGoogle Scholar
  21. 21.
    Kim, K.A., S.B. Chung, E.Y. Hawng, S.H. Noh, K.H. Song, H.H. Kim, C.H. Kim, and Y.G. Park. 2013. Correlation of expression and activity of matrix metalloproteinase-9 and -2 in human gingival cells of periodontitis patients. Journal Periodontal Implant Science. 43 (1): 24–29.CrossRefGoogle Scholar
  22. 22.
    Suh, S.J., C.H. Kwak, K.H. Song, K.M. Kwon, T.W. Chung, S.H. Cho, Y.K. Kim, H.D. Yoon, Y.C. Lee, D.S. Kim, S.J. Park, M.K. Na, J.K. Son, H.W. Chang, and C.H. Kim. 2012. Triple inhibitory activity of Cliona celata against TNF-α-induced matrix metalloproteinase-9 production via downregulated NF-κB and AP-1, enzyme activity, and migration potential. Inflammation. 35 (2): 736–745.CrossRefGoogle Scholar
  23. 23.
    Lee, S.H., C.H. Kwak, S.K. Lee, S.H. Ha, J. Park, T.W. Chung, K.T. Ha, S.J. Suh, Y.C. Chang, H.W. Chang, Y.C. Lee, B.S. Kang, J. Magae, and C.H. Kim. 2016. Anti-inflammatory effect of ascochlorin in LPS-stimulated RAW 264.7 macrophage cells is accompanied with the down-regulation of iNOS, COX-2 and proinflammatory cytokines through NF-κB, ERK1/2, and p38 signaling pathway. Journal of Cellular Biochemistry 117 (4): 978–987.CrossRefGoogle Scholar
  24. 24.
    Kim, K.W., K.T. Ha, C.S. Park, U.H. Jin, H.W. Chang, I.S. Lee, and C.H. Kim. 2007. Polygonum cuspidatum, compared with baicalin and berberine, inhibits inducible nitric oxide synthase and cyclooxygenase-2 gene expressions in RAW 264.7 macrophages. Vascular Pharmacology 47 (2–3): 99–107.CrossRefGoogle Scholar
  25. 25.
    Derrick, S.C., and S.L. Morris. 2007. The ESAT6 protein of Mycobacterium tuberculosis induces apoptosis of macrophages by activating caspase expression. Cellular Microbiology 9 (6): 1547–1555.CrossRefGoogle Scholar
  26. 26.
    Jung, B.G., X. Wang, N. Yi, J. Ma, J. Turner, and B. Samten. 2017. Early secreted antigenic target of 6-kDa of Mycobacterium tuberculosis stimulates IL-6 production by macrophages through activation of STAT3. Scientific Reports 7: 40984.  https://doi.org/10.1038/srep40984.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ganguly, N., P.H. Giang, S.K. Basu, F.A. Mir, I. Siddiqui, and P. Sharma. 2007. Mycobacterium tuberculosis 6-kDa early secreted antigenic target (ESAT-6) protein downregulates lipopolysaccharide induced c-myc expression by modulating the extracellular signal regulated kinases 1/2. BMC Immunology 8: 24.CrossRefGoogle Scholar
  28. 28.
    Pathak, S.K., S. Basu, K.K. Basu, A. Banerjee, S. Pathak, A. Bhattacharyya, T. Kaisho, M. Kundu, and J. Basu. 2007 Jun. Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages. Nature Immunology 8 (6): 610–618.CrossRefGoogle Scholar
  29. 29.
    Woo, C.H., J.H. Lim, and J.H. Kim. 2004. Lipopolysaccharide induces matrix metalloproteinase-9 expression via a mitochondrial reactive oxygen species-p38 kinase-activator protein-1 pathway in Raw 264.7 cells. Journal of Immunology 173 (11): 6973–6980.CrossRefGoogle Scholar
  30. 30.
    Yang, K., Y. Wu, H. Xie, M. Li, S. Ming, L. Li, M. Li, M. Wu, S. Gong, and X. Huang. 2016. Macrophage-mediated inflammatory response decreases mycobacterial survival in mouse MSCs by augmenting NO production. Scientific Reports 6: 27326.CrossRefGoogle Scholar
  31. 31.
    Zhang, Q., X. Jiang, W. He, K. Wei, J. Sun, X. Qin, et al. 2017. MCL plays an anti-inflammatory role in Mycobacterium tuberculosis-induced immune response by inhibiting NF-κB and NLRP3 inflammasome activation. Mediators of Inflammation 2017: 2432904.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Hakim, J.G., I. Ternouth, E. Mushangi, S. Siziya, V. Robertson, and A. Malin. 2000. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart. 84: 183–188.CrossRefGoogle Scholar
  33. 33.
    Ling, H., H. Yang, S.H. Tan, W.K. Chui, and E.H. Chew. 2010. 6-Shogaol, an active constituent of ginger, inhibits breast cancer cell invasion by reducing matrix metalloproteinase-9 expression via blockade of nuclear factor-κB activation. British Journal of Pharmacology 161: 1763–1777.CrossRefGoogle Scholar
  34. 34.
    Ghosh, S., and M. Karin. 2002. Missing pieces in the NF-kappaB puzzle. Cell. 109 (Suppl): S81–S96.CrossRefGoogle Scholar
  35. 35.
    LoBue, P.A., D.A. Enarson, and T.C. Thoen. 2010. Tuberculosis in humans and its epidemiology, diagnosis and treatment in the United States. The International Journal of Tuberculosis and Lung Disease 14: 1226–1232.PubMedGoogle Scholar
  36. 36.
    Sulis, G., A. Roggi, A. Matteelli, and M.C. Raviglione. 2014. Tuberculosis: epidemiology and control. The Mediterranean Journal of Hematology and Infectious Diseases 6: e2014070.CrossRefGoogle Scholar
  37. 37.
    Patel, K., S.S. Jhamb, and P.P. Singh. 2011. Models of latent tuberculosis: their salient features, limitations, and development. Journal Laboratory Physicians. 3: 75–79.CrossRefGoogle Scholar
  38. 38.
    Fujiwara, N., and K. Kobayashi. 2005. Macrophages in inflammation. Current Drug Targets. Inflammation and Allergy 4: 281–286.CrossRefGoogle Scholar
  39. 39.
    Kim, J.R., and C.H. Kim. 2004. Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells. The International Journal of Biochemistry & Cell Biology 36 (11): 2293–2306.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Sun-Hyung Ha
    • 1
  • Hyunju Choi
    • 1
  • Jun-Young Park
    • 1
  • Fukushi Abekura
    • 1
  • Young-Choon Lee
    • 2
  • Jeong-Ran Kim
    • 3
    Email author
  • Cheorl-Ho Kim
    • 1
    Email author
  1. 1.Molecular and Cellular Glycobiology Unit, Department of Biological SciencesSungkyunkwan UniversityJangan-guRepublic of Korea
  2. 2.Faculty of Medicinal BiotechnologyDong-A UniversityBusanRepublic of Korea
  3. 3.Department of Research and DevelopmentThe Korean Institute of TuberculosisCheongju-siRepublic of Korea

Personalised recommendations